NICE guidance rejects the use of Respreeza for alpha-1 antitrypsin deficiency.- CSL Behring.
The National Institute for Health and Care Excellence (NICE) has published draft guidelines that does not support the use by the NHS of Respreeza (alpha1-antitrypsin) from CSL Behring, for treating emphysema in adults with severe alpha-1-proteinase inhibitor deficiency. NICE suggests that though the available evidence points to the fact that the therapy slows progression of lung tissue damage compared with placebo and that treatment may improve patient survival, it remains unconvinced that Respreeza improves lung function or quality of life. The NICE committee concluded that cost-effectiveness estimates for the drug are beyond the range NICE normally considers acceptable.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins